Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
12:00 AM - DEVICE TALKS
9
11
12
13
14
16
18
19
20
21
22
23
24
26
27
28
29
30
31
1
2
3
4
DEVICE TALKS
DEVICE TALKS BOSTON 2018: BIGGER AND BETTER THAN EVER! Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it [...]
6th Annual HealthIMPACT Midwest
2018-10-10    
All Day
REV1 VENTURES COLUMBUS, OH The Provider-Patient Experience Summit - Disrupting Delivery without Disrupting Care HealthIMPACT Midwest is focused on technologies impacting clinician satisfaction and performance. [...]
15 Oct
2018-10-15 - 2018-10-16    
All Day
Conference Series Ltd invites all the participants from all over the world to attend “3rd International Conference on Environmental Health” during October 15-16, 2018 in Warsaw, Poland which includes prompt keynote [...]
17 Oct
2018-10-17 - 2018-10-19    
7:00 am - 6:00 pm
BALANCING TECHNOLOGY AND THE HUMAN ELEMENT In an era when digital technologies enable individuals to track health statistics such as daily activity and vital signs, [...]
Epigenetics Congress 2018
2018-10-25 - 2018-10-26    
All Day
Conference: 5th World Congress on Epigenetics and Chromosome Date: October 25-26, 2018 Place: Istanbul, Turkey Email: epigeneticscongress@gmail.com About Conference: Epigenetics congress 2018 invites all the [...]
Events on 2018-10-08
DEVICE TALKS
8 Oct 18
425 Summer Street
Events on 2018-10-10
Events on 2018-10-17
17 Oct
Events on 2018-10-25
Epigenetics Congress 2018
25 Oct 18
Istanbul
Press Releases

New Computational Model by CHOP Researchers Identifies Noncoding Mutations Across Five Pediatric Cancers

CHOP

New Computational Model by CHOP Researchers Identifies Noncoding Mutations Across Five Pediatric Cancers

Researchers at Children’s Hospital of Philadelphia (CHOP) have developed a new computational algorithm that has, for the first time, identified a spectrum of mutations in the noncoding portion of the human genome across five major pediatric cancers. The study, which was published today in Science Advances, used the algorithm to analyze more than 500 pediatric cancer patients’ mutations and gene expression profiles to develop a comprehensive list of potentially cancer-causing mutations.

“Noncoding mutations are very important because the noncoding portion of the genome typically regulates how genes are turned on and off, much like a control switch, which has implications for the uncontrolled growth that occurs in cancer,” said Kai Tan, PhD, Professor of Pediatrics at CHOP and senior author of the study. “However, these regions are also challenging to study, and our knowledge about them not as developed as that of coding regions. Our computational model has identified a set of targets in pediatric cancers that we hope to study further and eventually move to clinical practice.”

The researchers developed a computation tool called PANGEA (predictive analysis of noncoding genomic enhancer/promoter alterations) to analyze noncoding mutations and their impact on gene expression in more than 500 pediatric cancer patients who had five major types of pediatric cancer: B cell acute lymphoblastic leukemia (B-ALL), acute myeloid leukemia (AML), neuroblastoma, Wilms tumor, and osteosarcoma. PANGEA identified all types of mutations that are associated with gene expression changes, including single nucleotide variants, small indels, copy number variations, and structural variants.

Previous studies on noncoding mutations have focused on single nucleotide variants and small indels, which are insertions or deletions of bases in the genome that are relatively short in length. However, structural variants are regions of DNA much larger in size – 1 kilobase or larger – a quality that makes them more difficult to identify but also more likely to contribute to changes in gene regulation that lead to cancer.

Using PANGEA, the researchers found that structural variants are indeed the most frequent cause of potentially cancer-causing mutations and identified 1,137 structural variants that affect the expression of more than 2,000 genes across the five pediatric cancer types.

In analyzing the data, the researchers found that coding and noncoding mutations affect distinct sets of genes and pathways, which is likely due to the different genomic locations of these two types of genes. The researchers found that genes involved in metabolism – the rewiring of which is a hallmark of cancer – are more frequently affected by noncoding mutations. However, it is unclear to what degree noncoding mutations facilitate metabolism rewiring in the five cancer types the researchers studied.

“Our results highlight the need for comparative analysis of both coding and noncoding mutations, which might reveal novel cancer-related genes and pathways,” said Tan. “Identifying putative mutations is a starting point that will facilitate experimental work to validates these predictions.”

This work was supported by grants from the National Institutes of Health, including the National Cancer Institute and the National Institute of General Medical Sciences.

About Children’s Hospital of Philadelphia

Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children’s Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 564-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Source